Short Bowel Syndrome

Categories: Rare diseases, Gastrointestinal diseases, Genetic diseases, Fetal diseases

Aliases & Classifications for Short Bowel Syndrome

MalaCards integrated aliases for Short Bowel Syndrome:

Name: Short Bowel Syndrome 12 76 53 37 55 44 15 73
Acquired Short Bowel Syndrome 12
Short Gut Syndrome 12


External Ids:

Disease Ontology 12 DOID:10605
MeSH 44 D012778
NCIt 50 C99059
KEGG 37 H01469
UMLS 73 C0036992

Summaries for Short Bowel Syndrome

NIH Rare Diseases : 53 Short bowel syndrome is a disorder characterized by malabsorption of nutrients due to problems involving the small intestine. The small intestine is the tube-shaped organ between the stomach and large intestine, which includes the duodenum, jejunum, and ileum, where most food digestion and nutrient absorption take place. The causes of short bowel syndrome in adults include Crohn disease, mesenteric ischemia, radiation enteritis, or surgical removal of half or more of the small intestine to treat intestinal diseases or injuries. In children the main causes include necrotizing enterocolitis, intestinal atresias, and intestinal volvulus. Signs and symptoms may include diarrhea, cramping, bloating, heartburn, dehydration, malnutrition, weight loss, food sensitivities, weakness, and fatigue. Examples of treatment include diet and nutritional support, intestinal surgeries, and, in some cases, intestinal transplantation.

MalaCards based summary : Short Bowel Syndrome, also known as acquired short bowel syndrome, is related to congenital short bowel syndrome and intestinal pseudo-obstruction, and has symptoms including pain, postoperative and postoperative nausea and vomiting. An important gene associated with Short Bowel Syndrome is CLMP (CXADR Like Membrane Protein), and among its related pathways/superpathways are Signaling by GPCR and Focal Adhesion. The drugs Ursodeoxycholic acid and Lactulose have been mentioned in the context of this disorder. Affiliated tissues include small intestine, liver and kidney, and related phenotype is growth/size/body region.

Wikipedia : 76 Short bowel syndrome (SBS, or simply short gut) is a malabsorption disorder caused by a lack of... more...

Related Diseases for Short Bowel Syndrome

Diseases in the Short Bowel Syndrome family:

Congenital Short Bowel Syndrome Secondary Short Bowel Syndrome

Diseases related to Short Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 congenital short bowel syndrome 34.8 CLMP FLNA
2 intestinal pseudo-obstruction 32.0 CLMP FLNA SST
3 gastrointestinal system disease 28.9 CCK GCG PYY SST
4 secondary short bowel syndrome 12.0
5 intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked 11.9
6 gastroschisis 11.2
7 primary optic atrophy 10.7 FLNA GCG
8 vipoma 10.5 NTS SST
9 pancreatoblastoma 10.5 NTS SST
10 zollinger-ellison syndrome 10.5 NTS SST
11 diaphragmatic eventration 10.4 EGF FLNA
12 postcholecystectomy syndrome 10.4 CCK SST
13 duodenal gastrinoma 10.3 CCK SST
14 functional gastric disease 10.3 CCK SST
15 steatorrhea 10.2 CCK SST
16 postgastrectomy syndrome 10.2 NTS PYY SST
17 liver disease 10.2
18 rasmussen encephalitis 10.2 CCK SST
19 pain agnosia 10.1 CCK NTS
20 crohn's disease 10.1
21 pancreatic cholera 10.1 CCK GCG SST
22 acidophil adenoma 10.1 IGF1 SST
23 lactic acidosis 10.1
24 pituitary infarct 10.0 IGF1 SST
25 serotonin syndrome 10.0 PYY SST
26 hormone producing pituitary cancer 10.0 IGF1 SST
27 morbid obesity 10.0 CCK GCG PYY
28 pituitary adenoma 1, multiple types 10.0 IGF1 SST
29 agnosia 10.0 CCK NTS
30 burns 10.0 HGF TTR
31 hyperpituitarism 10.0 IGF1 SST
32 enterocolitis 10.0
33 perinatal necrotizing enterocolitis 10.0
34 mucositis 9.9
35 diarrhea 9.9
36 cholestasis 9.9
37 dumping syndrome 9.9 GCG NTS PYY SST
38 infantile liver failure syndrome 1 9.8
39 hepatitis 9.8
40 pancreatitis 9.8
41 encephalopathy 9.8
42 donohue syndrome 9.8 EGF IGF1
43 acrodermatitis enteropathica, zinc-deficiency type 9.7
44 arthritis 9.7
45 metabolic acidosis 9.7
46 thrombosis 9.7
47 xerophthalmia 9.7
48 intestinal atresia 9.7
49 osteomalacia 9.7
50 acrodermatitis 9.7

Graphical network of the top 20 diseases related to Short Bowel Syndrome:

Diseases related to Short Bowel Syndrome

Symptoms & Phenotypes for Short Bowel Syndrome

UMLS symptoms related to Short Bowel Syndrome:

pain, postoperative, postoperative nausea and vomiting

MGI Mouse Phenotypes related to Short Bowel Syndrome:

# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.23 CLMP EGF FLNA HGF IGF1 NTS

Drugs & Therapeutics for Short Bowel Syndrome

Drugs for Short Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
Lactulose Approved Phase 4 4618-18-2 11333
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
4 glucagon Phase 4,Phase 1,Phase 2,Not Applicable
5 Glucagon-Like Peptide 1 Phase 4,Phase 2,Phase 1,Not Applicable
6 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
Bilirubin Phase 4,Phase 2,Phase 3 635-65-4 5280352
8 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Fat Emulsions, Intravenous Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Parenteral Nutrition Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Soybean oil, phospholipid emulsion Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Incretins Phase 4,Phase 2,Phase 1,Not Applicable
17 Cholagogues and Choleretics Phase 4
18 Fibrinolytic Agents Phase 4
19 Plasminogen Phase 4
20 Tissue Plasminogen Activator Phase 4
21 N-Methylaspartate Phase 4
22 Dipeptidyl-Peptidase IV Inhibitors Phase 4
23 HIV Protease Inhibitors Phase 4
24 Hypoglycemic Agents Phase 4,Phase 2
protease inhibitors Phase 4
26 Sitagliptin Phosphate Phase 4
27 Soy Bean Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 alanine Nutraceutical Phase 4,Not Applicable
29 Aspartic Acid Nutraceutical Phase 4
30 glutamine Nutraceutical Phase 4,Not Applicable
31 Olive Nutraceutical Phase 4,Phase 3
32 Phytosterol Nutraceutical Phase 4
Ampicillin Approved, Vet_approved Phase 2, Phase 3 69-53-4 6249
Clindamycin Approved, Vet_approved Phase 2, Phase 3 18323-44-9 29029
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
Piperacillin Approved Phase 2, Phase 3 66258-76-2 43672
Tazobactam Approved Phase 2, Phase 3 89786-04-9 123630
38 Atosiban Approved, Investigational Phase 3 90779-69-4
Loperamide Approved Phase 3,Phase 1 53179-11-6 3955
40 Anti-Bacterial Agents Phase 2, Phase 3
41 Antibiotics, Antitubercular Phase 2, Phase 3
42 Anti-Infective Agents Phase 2, Phase 3
43 Antiparasitic Agents Phase 2, Phase 3
44 Antiprotozoal Agents Phase 2, Phase 3
45 Antitubercular Agents Phase 2, Phase 3
46 beta-Lactamase Inhibitors Phase 2, Phase 3
47 Clindamycin palmitate Phase 2, Phase 3
48 Clindamycin phosphate Phase 2, Phase 3
49 Gentamicins Phase 2, Phase 3
50 Penicillanic Acid Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 Short Bowel Syndrome and Teduglutide Versus Placebo Completed NCT02099084 Phase 4 Teduglutide;Placebo
2 The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients Completed NCT01974336 Phase 4 ursodeoxycholic acid
3 rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome Completed NCT02355743 Phase 4 rtPA lock therapy
4 rHGH and Intestinal Permeability in Intestinal Failure Completed NCT01380366 Phase 4 Somatropin
5 The Use of DPP-4 Inhibitors in Short Bowel Syndrome Recruiting NCT02653131 Phase 4 Dipeptidyl peptidase-4 inhibitor
6 Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients Not yet recruiting NCT03562130 Phase 4 Teduglutide
7 A 90 Day, Phase 4,Open Labeled Exploratory Study of RELiZORB Not yet recruiting NCT03530852 Phase 4
8 Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS) Terminated NCT00742157 Phase 4 Growth Hormone
9 Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion Terminated NCT02476994 Phase 4 Clinolipid;Intralipid
10 Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome Withdrawn NCT01818648 Phase 4 Exenatide;Placebo
11 SMOFLipid in Patients Who Are Intralipid Intolerant Withdrawn NCT03054948 Phase 4 SMOFLipid;Standard therapy
12 Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome Completed NCT00169637 Phase 3 rhGH
13 Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition Completed NCT02682381 Phase 3 Teduglutide 0.05mg/kg;Teduglutide 0.025 mg/kg
14 Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Completed NCT00081458 Phase 3 Placebo;Teduglutide 0.05 mg/kg/d;Teduglutide 0.1 mg/kg/d
15 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects Completed NCT00798967 Phase 3 teduglutide;placebo
16 A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Completed NCT01952080 Phase 3 teduglutide
17 Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS) Completed NCT00930644 Phase 3 teduglutide
18 Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) Completed NCT00172185 Phase 3 teduglutide 0.05 mg/kg/d;teduglutide 0.10 mg/kg/d
19 A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021 Completed NCT01560403 Phase 3 Teduglutide
20 Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients Completed NCT00802503 Phase 3
21 Antibiotic Safety (SCAMP) Completed NCT01994993 Phase 2, Phase 3 ampicillin and metronidazole and gentamicin;ampicillin and gentamicin and clindamycin;gentamicin and Piperacillin- tazobactam;standard of care antibiotics and metronidazole;metronidazole, clindamycin, or piperacillin-tazobactam
22 A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 Recruiting NCT03268811 Phase 3 Teduglutide
23 Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support Recruiting NCT02980666 Phase 3 Teduglutide
24 Cholestasis Reversal: Efficacy of IV Fish Oil Recruiting NCT00910104 Phase 2, Phase 3 Omegaven®
25 Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children Recruiting NCT01194063 Phase 3 Omega-3 fish oil lipid emulsion
26 Compassionate Use of Omegaven in Children Recruiting NCT02370251 Phase 2, Phase 3 Omegaven
27 Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study Active, not recruiting NCT02949362 Phase 3 Teduglutide
28 Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS) Active, not recruiting NCT02954458 Phase 3 TED
29 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS) Active, not recruiting NCT02340819 Phase 3 Teduglutide
30 Safety and Efficacy Study in Infant With SBS Active, not recruiting NCT02865122 Phase 2, Phase 3 NTRA-9620;Placebo
31 Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies Active, not recruiting NCT02292784 Phase 3 Retosiban;Atosiban;Placebo
32 Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Not yet recruiting NCT03571516 Phase 3 Teduglutide
33 Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates Not yet recruiting NCT03387579 Phase 3 Lipid Emulsions, Intravenous;Intralipid, 20% Intravenous Emulsion
34 Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study Terminated NCT02266849 Phase 3 Loperamide;Placebo
35 A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals Withdrawn NCT02242656 Phase 3 Opium Tincture USP Deodorized;Opium Tincture USP Deodorized
36 A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 Withdrawn NCT02246816 Phase 3 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
37 Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease Unknown status NCT01739517 Phase 2 Omegaven Therapy
38 Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? Unknown status NCT00793195 Phase 2 Intralipid 20%;SMOFlipid 20%
39 A Phase 2 Trial Testing ZP1848 in Patients With SBS Completed NCT02690025 Phase 2 ZP1848
40 Diet/Growth Factor Mechanisms of Gut Adaptation Completed NCT00067860 Phase 2 recombinant human growth hormone
41 Use of Pancreatic Enzymes in Short Bowel Syndrome Recruiting NCT03097029 Phase 2 Pancreatic Enzyme
42 Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) Recruiting NCT03371862 Phase 2 Liraglutide Pen Injector [Victoza]
43 Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis Recruiting NCT02148146 Phase 1, Phase 2 Omegaven
44 Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury Recruiting NCT01845116 Phase 2 Omegaven®
45 Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support Not yet recruiting NCT03415594 Phase 1, Phase 2 FE203799 GLP-2 analogue;FE203799 Placebo GLP-2 analogue
46 Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency Not yet recruiting NCT03408132 Phase 1, Phase 2 FE203799
47 Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure Terminated NCT01573286 Phase 1, Phase 2 Glucagon-Like Peptide 2;Glucagon like peptide-2
48 Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome Withdrawn NCT01263574 Phase 2 70% ethanol
49 Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease Withdrawn NCT01191177 Phase 1, Phase 2 Lovaza (omega-3-acid ethyl ester)
50 Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome Completed NCT00767364 Phase 1

Search NIH Clinical Center for Short Bowel Syndrome

Cochrane evidence based reviews: short bowel syndrome

Genetic Tests for Short Bowel Syndrome

Anatomical Context for Short Bowel Syndrome

MalaCards organs/tissues related to Short Bowel Syndrome:

Small Intestine, Liver, Kidney, Colon, Bone, Testes, Skin

Publications for Short Bowel Syndrome

Articles related to Short Bowel Syndrome:

(show top 50) (show all 689)
# Title Authors Year
Metabolic acidosis in short bowel syndrome: think D-lactic acid acidosis. ( 29769189 )
Nutritional therapy complications in children with ultra-short bowel syndrome include growth deficiency but not cholestasis. ( 29405447 )
What's new in short bowel syndrome? ( 29702489 )
Energy intake in short bowel syndrome: assessment by 24-h dietary recalls compared with the doubly labelled water method. ( 29268807 )
Chapter 5.2.1. Short Bowel Syndrome: Half a Century of Progress. ( 29596171 )
Nutritional Therapy in Adult Short Bowel Syndrome Patients with Chronic Intestinal Failure. ( 29413019 )
Bacteria, Bones, and Stones: Managing Complications of Short Bowel Syndrome. ( 29926935 )
Three-dimensional CT enterography versus barium follow-through examination in measurement of remnant small intestinal length in short bowel syndrome patients. ( 29700592 )
The protective effect of fish oil lipid emulsions on intestinal failure-associated liver disease in a rat model of short-bowel syndrome. ( 29039050 )
Ostomy in continuity: A novel approach for the management of children with complex short bowel syndrome. ( 29602547 )
Prophylactic cholecystectomy in short bowel syndrome: Is it being utilized? ( 29753389 )
Duodenocolostomy as Treatment of Ileus in Short Bowel Syndrome: A Case Report. ( 29976919 )
Congenital Short-Bowel Syndrome in an Adult Dog. ( 29310549 )
Outcomes in patients with short bowel syndrome after autologous intestinal reconstruction: Does etiology matter? ( 29628209 )
Innovative Discharge Process for Families with Pediatric Short Bowel Syndrome: A Prospective Nonrandomized Trial. ( 29603317 )
Impact of Short Bowel Syndrome on Quality of Life and Family: The Patient's Perspective. ( 29532454 )
Is Serum Methylmalonic Acid a Reliable Biomarker of Vitamin B12 Status in Children with Short Bowel Syndrome: A Case Series. ( 29129351 )
Teduglutide for the treatment of short bowel syndrome - a safety evaluation. ( 29848084 )
Intestinal adaptation in short bowel syndrome. What is new? ( 29974785 )
Surgical revascularization of the celiac artery for persistent intestinal ischemia in short bowel syndrome. ( 29247810 )
Further improvement after 24-month treatment with teduglutide in a patient with active Crohn's disease and short bowel syndrome. ( 29749341 )
Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study. ( 29761915 )
We Cannot Say Biologic Therapy Is Not Useful in Patients With Short-Bowel Syndrome From Resections Related to Crohn's Disease, nor Can We Conclude They Are of Value. ( 29678241 )
Segmental reversal of distal small intestine in short bowel syndrome: a study on the influence on postoperative weight and intestinal topography in piglets. ( 29666926 )
Duodenal lengthening in an adult with ultra-short bowel syndrome. A case report. ( 29106286 )
Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series. ( 29603279 )
Soluble Fiber Use in Pediatric Short Bowel Syndrome: A Survey on Prevailing Practices. ( 29767462 )
Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. ( 29732709 )
Clinical Report: Intestinal Rehabilitation Programs in the Management of Pediatric Intestinal Failure and Short Bowel Syndrome. ( 28837507 )
Prevalence and risk factors for complications in adult patients with short bowel syndrome receiving long-term home parenteral nutrition. ( 28582806 )
Anastomotic ulcers in short bowel syndrome: New suggestions from a multidisciplinary approach. ( 28610705 )
Current treatment paradigms in pediatric short bowel syndrome. ( 29280097 )
Short Bowel Syndrome: An Uncommon Clinical Entity and a Therapeutic Challenge-Our Experience and Review of Literature. ( 28827911 )
Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ( 29127863 )
Radiographic measurement of intestinal length among children with short bowel syndrome: Retrospective determination remains problematic. ( 28987713 )
Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. ( 29174926 )
A Twist in the Tale of a Pig Model of Short-Bowel Syndrome. ( 29204506 )
Small bowel dilation in children with short bowel syndrome is associated with mucosal damage, bowel-derived bloodstream infections, and hepatic injury. ( 28689603 )
Enteral Autonomy with Teduglutide Treatment of Intestinal Failure/Short Bowel Syndrome with Depleted Central Venous Access. ( 28993968 )
Managing the Adult Patient With Short Bowel Syndrome. ( 29230136 )
Anaphylactic shock with methylprednisolone sodium succinate in a child with short bowel syndrome and cow's milk allergy. ( 29149860 )
A Pilot Study Comparing 2 Oral Rehydration Solutions in Patients With Short Bowel Syndrome Receiving Home Parenteral Nutrition: A Prospective Double-Blind Randomized Controlled Trial. ( 28662613 )
Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome. ( 28783205 )
Tissue engineering for the treatment of short bowel syndrome in children. ( 28937976 )
Effect of Splenectomy to Short Bowel Syndrome in Rats. ( 28659672 )
Acrodermatitis enteropathica in a patient with short bowel syndrome. ( 29232432 )
Intensive Nutrition Management in a Patient with Short Bowel Syndrome Who Underwent Bariatric Surgery. ( 28770185 )
De Novo Development of Hamartomatous Duodenal Polyps in a Patient With Short Bowel Syndrome During Teduglutide Therapy: A Case Report. ( 28666089 )
A case of osteomalacia due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome: A case report. ( 28953654 )
Oral Feeding Difficulties in Children With Short Bowel Syndrome: A Narrative Review. ( 28521656 )

Variations for Short Bowel Syndrome

Expression for Short Bowel Syndrome

Search GEO for disease gene expression data for Short Bowel Syndrome.

Pathways for Short Bowel Syndrome

GO Terms for Short Bowel Syndrome

Cellular components related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CCK EGF GCG HGF IGF1 PYY
2 platelet alpha granule lumen GO:0031093 9.33 EGF HGF IGF1
3 extracellular region GO:0005576 9.32 CCK EGF FLNA GCG HGF IGF1

Biological processes related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.95 CCK GCG NTS PYY SST
2 negative regulation of apoptotic process GO:0043066 9.83 FLNA GCG HGF IGF1
3 positive regulation of cell proliferation GO:0008284 9.8 CCK EGF HGF IGF1
4 positive regulation of cell migration GO:0030335 9.71 EGF HGF IGF1
5 cell proliferation GO:0008283 9.67 GCG HGF IGF1 PYY
6 feeding behavior GO:0007631 9.56 GCG PYY
7 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.51 EGF GCG
8 activation of MAPK activity GO:0000187 9.5 EGF HGF IGF1
9 ERK1 and ERK2 cascade GO:0070371 9.48 EGF IGF1
10 positive regulation of DNA binding GO:0043388 9.46 EGF IGF1
11 platelet degranulation GO:0002576 9.46 EGF FLNA HGF IGF1
12 positive regulation of mitotic nuclear division GO:0045840 9.43 EGF IGF1
13 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.4 HGF IGF1
14 myoblast proliferation GO:0051450 9.26 HGF IGF1
15 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.26 CCK EGF HGF IGF1
16 regulation of signaling receptor activity GO:0010469 9.23 CCK GCG HGF IGF1 NTS PYY

Molecular functions related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 EGF HGF IGF1
2 neuropeptide hormone activity GO:0005184 9.13 CCK NTS PYY
3 hormone activity GO:0005179 9.1 CCK GCG IGF1 PYY SST TTR

Sources for Short Bowel Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....